Navigation Links
Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO

VANCOUVER, British Columbia, Jan. 4, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has appointed John C. Rewcastle, Ph.D., as Chief Executive Officer.

Prior to joining Enox, Dr. Rewcastle served as Medical Director of EDAP TMS S.A. (Nasdaq: EDAP) and also cofounded Firma Medical, a private medical device company. Prior to this, he served as Chief Scientific Officer of Sanarus Medical, Inc. and also led the research department of Endocare, Inc. which is now owned by Endo Pharmaceuticals. Concurrent with his industry experience, Dr. Rewcastle served as an Adjunct Assistant Professor of Radiology at the University of Calgary where he had completed his Ph.D. which focused on the development and characterization of medical devices. He has authored over 40 peer reviewed journal articles and medical text book chapters.

"John brings significant medical device industry experience to Enox and our ability to recruit a veteran of the medical device industry speaks to the compelling potential of the Enox technology," said Enox Founder and President Professor Yossef Av-Gay. "As we focus on FDA approval and commercialization of devices combined with Nitric Oxide impregnation, John's leadership and experience will be invaluable."

Dr. Rewcastle commented, "Enox has harnessed the body's own mechanism of action to block microbial growth on medical devices without the use of antibiotics. Potentially, this is a solution to one of the biggest problems facing patients and hospitals today: hospital acquired infections. The regulatory and reimbursement paths should be relatively straight forward. Nitric Oxide has an already established safety profile as it is FDA approved for respiratory treatment of neonates. In the United States, Medicare no longer pays hospitals for the treatment of hospital acquired infections; meaning that their cost comes out of hospital profits."

Rewcastle continued, "The fact that the Enox technology can be applied to any polymer medical device including silicone, and that the medical system is massively burdened by the cost of treating infections, yields a truly unique opportunity. Leading a company that has the potential of benefiting patients, physicians and hospitals, while significantly reducing the overall cost of healthcare, is a challenge I welcome with confidence and pride."About Enox Biopharma, Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymeric medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymeric medical device including, but not limited to, catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them uniquely antimicrobial. Reducing infection rates without antibiotics benefits patients, physicians, hospitals and decreases the overall cost of health care.

Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.For more information, please contact:John C. Rewcastle, Ph.D., CEO orItamar David, CFOEnox Biopharma, Inc.604.637.9744 phone888.224.7259

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma, Inc. Appoints New Director of Marketing
2. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
3. Laureate Pharma Appoints Kathleen P. Bloch as Chief Financial Officer
4. China-Biotics Appoints New Chief Operating Officer
5. BioStorage Technologies Appoints New Vice President of Global Sales
6. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
7. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
8. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
9. caprotec bioanalytics GmbH Appoints Prof. Dr. Rainer Metternich as Managing Director, Chief Business Officer and Chief Operating Officer
10. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
11. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
Breaking Biology Technology:
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):